Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Abstract Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season. In this pre-specified analysi...
Main Authors: | Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-40057-8 |
Similar Items
-
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
by: Bahar Ahani, et al.
Published: (2024-04-01) -
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
by: Tyler Brady, et al.
Published: (2023-10-01) -
The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
by: Maria Wilma R. Turalde-Mapili, et al.
Published: (2023-04-01) -
Potential Effects on Elderly People From Nirsevimab Use in Infants
by: Iván Sanz-Muñoz, et al.
Published: (2024-04-01) -
Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
by: Getu Zhaori
Published: (2023-06-01)